Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program

Learn how de-risk early-stage CMC and delivery of clinical trials material by addressing the challenges faced when therapeutic antibodies show less-than-ideal properties, from early antibody development through to downstream manufacturing to pre-clinical and clinical studies.

Access this on-demand webinar: